Skip to main content
Centessa Pharmaceuticals plc logo

Centessa Pharmaceuticals plc — Investor Relations & Filings

Ticker · CNTA ISIN · US1523091007 LEI · 213800GIDAARDSKOI827 US Manufacturing
Open in API
Filings indexed 548 across all filing types
Latest filing 2022-12-23 Capital/Financing Update
Country GB United Kingdom
Listing US CNTA

About Centessa Pharmaceuticals plc

https://www.centessa.com/

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that utilizes a Research & Development innovation engine to discover and develop transformational medicines for patients. The company employs a data-driven approach to advance its portfolio of innovative assets. A key program in its pipeline is the development of potential best-in-class, orally administered orexin receptor 2 (OX2R) agonists for the treatment of sleep-wake disorders. Centessa's broader therapeutic focus often includes rare diseases and other areas with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a waiver related to a Note Purchase Agreement and an Event of Default due to a subsidiary's legal name change. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about a financing event and waiver. The document length is 4443 characters, which is relatively short and focused on a specific event. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to financing arrangements and waivers under a loan agreement.
2022-12-23 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 10, 2022. It includes disclosures about a presentation of clinical data at the ASH Annual Meeting and a press release about the same. The document contains no detailed financial statements or comprehensive financial analysis. It primarily serves as a regulatory announcement of recent events and disclosures, including attached exhibits (presentation and press release). The document length is about 12,418 characters, which is moderate, but the content is clearly an event disclosure rather than a full financial report or earnings release. The presence of forward-looking statements and the nature of the content confirm it is a regulatory filing announcing material events. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-12-12 English
FORM 4
Director's Dealing
2022-12-05 English
FORM 3
Director's Dealing
2022-12-05 English
FORM 4
Director's Dealing
2022-12-05 English
FORM 4/A
Director's Dealing
2022-11-23 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.